JP7437301B2 - Ｂ７－ｈ４抗体及びその使用方法 - Google Patents

Ｂ７－ｈ４抗体及びその使用方法 Download PDF

Info

Publication number
JP7437301B2
JP7437301B2 JP2020511358A JP2020511358A JP7437301B2 JP 7437301 B2 JP7437301 B2 JP 7437301B2 JP 2020511358 A JP2020511358 A JP 2020511358A JP 2020511358 A JP2020511358 A JP 2020511358A JP 7437301 B2 JP7437301 B2 JP 7437301B2
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
seq
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500853A5 (enExample
JP2021500853A (ja
Inventor
チャールズ カプラン，
デリック ハウザー，
ルイス ボルジェス，
グロリア ブラティッチ，
デイビッド ベロヴィン，
フェリシア ケンプ，
マジッド ゴドゥシ，
ネルス ピー． ニールソン，
キャシー ミラー，
マイク シュミット，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2021500853A publication Critical patent/JP2021500853A/ja
Publication of JP2021500853A5 publication Critical patent/JP2021500853A5/ja
Priority to JP2024018525A priority Critical patent/JP7802101B2/ja
Application granted granted Critical
Publication of JP7437301B2 publication Critical patent/JP7437301B2/ja
Priority to JP2026000920A priority patent/JP2026053725A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020511358A 2017-08-25 2018-08-23 Ｂ７－ｈ４抗体及びその使用方法 Active JP7437301B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024018525A JP7802101B2 (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法
JP2026000920A JP2026053725A (ja) 2017-08-25 2026-01-06 Ｂ７－ｈ４抗体及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762550173P 2017-08-25 2017-08-25
US62/550,173 2017-08-25
US201762579774P 2017-10-31 2017-10-31
US62/579,774 2017-10-31
US201762607810P 2017-12-19 2017-12-19
US62/607,810 2017-12-19
US201862656789P 2018-04-12 2018-04-12
US62/656,789 2018-04-12
PCT/US2018/047805 WO2019040780A1 (en) 2017-08-25 2018-08-23 ANTI-B7-H4 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018525A Division JP7802101B2 (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021500853A JP2021500853A (ja) 2021-01-14
JP2021500853A5 JP2021500853A5 (enExample) 2021-10-07
JP7437301B2 true JP7437301B2 (ja) 2024-02-22

Family

ID=63490758

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511358A Active JP7437301B2 (ja) 2017-08-25 2018-08-23 Ｂ７－ｈ４抗体及びその使用方法
JP2024018525A Active JP7802101B2 (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法
JP2026000920A Pending JP2026053725A (ja) 2017-08-25 2026-01-06 Ｂ７－ｈ４抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024018525A Active JP7802101B2 (ja) 2017-08-25 2024-02-09 Ｂ７－ｈ４抗体及びその使用方法
JP2026000920A Pending JP2026053725A (ja) 2017-08-25 2026-01-06 Ｂ７－ｈ４抗体及びその使用方法

Country Status (21)

Country Link
US (4) US11306144B2 (enExample)
EP (1) EP3672990A1 (enExample)
JP (3) JP7437301B2 (enExample)
KR (2) KR20240138135A (enExample)
CN (2) CN111094352B (enExample)
AU (2) AU2018321902B2 (enExample)
BR (1) BR112020003533A2 (enExample)
CA (1) CA3070774A1 (enExample)
CL (4) CL2020000452A1 (enExample)
CO (1) CO2020001955A2 (enExample)
CR (2) CR20200138A (enExample)
EC (1) ECSP20020111A (enExample)
IL (2) IL272274B2 (enExample)
MA (1) MA49950A (enExample)
MX (3) MX2020002076A (enExample)
PE (1) PE20200797A1 (enExample)
PH (1) PH12020500368A1 (enExample)
SG (1) SG11202000387YA (enExample)
TW (2) TWI870011B (enExample)
UA (1) UA128472C2 (enExample)
WO (1) WO2019040780A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000387YA (en) 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
KR20240134250A (ko) 2018-01-04 2024-09-06 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019165077A1 (en) * 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
AU2019226009B2 (en) * 2018-02-21 2025-11-20 Five Prime Therapeutics, Inc. B7-H4 antibody dosing regimens
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2019361923B2 (en) * 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020242794B2 (en) * 2019-03-21 2024-02-01 Beijing Kanova Biopharmaceutical Co., Ltd. Anti-B7S1 polypeptides and their use
MX2021013272A (es) * 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
PE20221004A1 (es) * 2019-07-03 2022-06-15 Iconic Therapeutics Inc Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20230112085A1 (en) * 2020-01-30 2023-04-13 Apeximmune Therapeutics Inc. Anti-b7-h4 constructs and uses thereof
KR20220154757A (ko) * 2020-03-18 2022-11-22 젠맵 에이/에스 B7h4에 결합하는 항체
AU2021251875A1 (en) 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
JP7726534B2 (ja) 2020-06-30 2025-08-20 諾納生物（蘇州）有限公司 抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
WO2022002036A1 (zh) * 2020-06-30 2022-01-06 和铂医药(上海)有限责任公司 一种双特异性抗体及其用途
MX2023000662A (es) * 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
CN117980332A (zh) * 2020-08-18 2024-05-03 Abl生物公司 抗b7-h4/抗4-1bb双特异性抗体及其应用
JP2023539645A (ja) * 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022147532A1 (en) 2021-01-04 2022-07-07 Mersana Therapeutics, Inc. B7h4-targeted antibody-drug conjugates and methods of use thereof
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
KR20240004949A (ko) 2021-05-07 2024-01-11 젠맵 에이/에스 B7h4 및 cd3에 결합하는 이중특이적 항체를 포함하는 제약 조성물
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
IL308795A (en) 2021-05-28 2024-01-01 Seagen Inc Anthracycline antibody conjugates
KR20240099190A (ko) 2021-09-30 2024-06-28 씨젠 인크. 암 치료를 위한 b7-h4 항체 약물 접합체
MX2024006573A (es) 2021-12-01 2024-06-11 Kadmon Corp Llc Anticuerpos b7-h4 y anticuerpo anti-b7-h4/ proteinas de fusion il-15.
KR20250004952A (ko) 2022-03-17 2025-01-08 씨젠 인크. 캄프토테신 접합체
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies
CN116589580A (zh) * 2023-04-07 2023-08-15 福建医科大学 特异性靶向b7-h4的抗体及其制备方法和应用
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
TW202535940A (zh) 2023-10-24 2025-09-16 美商思進公司 化學治療化合物及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2015017600A1 (en) 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US7328387B2 (en) 2004-12-10 2008-02-05 Texas Instruments Incorporated Addressable tap domain selection circuit with selectable ⅗ pin interface
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US5672694A (en) 1995-10-24 1997-09-30 University Of Iowa Research Foundation β-sarcoglycan nucleic acid sequence, and nucleic acid probes
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20060223077A1 (en) 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US20030181692A1 (en) 1997-06-06 2003-09-25 Jian Ni 207 human secreted proteins
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
SE512112C2 (sv) 1998-12-03 2000-01-24 Scania Cv Ab Anordning för ventilation av ett utrymme i ett fordon
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
US20020146727A1 (en) 1999-11-30 2002-10-10 Dillon Davin C. Compositions and methods for the therapy and diagnosis of breast cancer
US20040142361A1 (en) 1999-11-30 2004-07-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU1807401A (en) 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU2001245308A1 (en) 2000-02-24 2001-09-03 Human Genome Sciences, Inc. 207 human secreted proteins
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
EP1301524A1 (en) 2000-06-30 2003-04-16 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2002016581A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1445318A2 (en) 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
JPWO2002030954A1 (ja) 2000-10-06 2004-02-19 協和醗酵工業株式会社 抗体を精製する方法
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002071928A2 (en) 2001-03-14 2002-09-19 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
WO2005035724A2 (en) 2003-10-08 2005-04-21 Avalon Pharmaceuticals, Inc Cancer-linked genes as targets for chemotherapy
WO2004058167A2 (en) 2002-12-20 2004-07-15 Avalon Pharmaceuticals, Inc. Breast specific protein expressed in cancer and methods of use thereof
WO2003097802A2 (en) 2002-05-16 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
WO2005062788A2 (en) 2003-12-22 2005-07-14 Avalon Pharmaceuticals, Inc. Prostate specific proteins expressed in cancer and methods of use thereof
US20060099214A1 (en) 2002-06-11 2006-05-11 Reinhard Ebner Cancer-linked gene as target for chemotherapy
US20050220798A1 (en) 2002-06-04 2005-10-06 Reinhard Ebner Cancer-linked gene as target for chemotherapy
WO2003076579A2 (en) 2002-03-06 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
CA2485983A1 (en) 2002-05-15 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
AU2003249691A1 (en) 2002-06-07 2003-12-22 Avalon Pharmaceuticals, Inc Cancer-linked gene as target for chemotherapy
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
EP1539218A4 (en) 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
KR101498588B1 (ko) 2003-01-22 2015-03-05 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US20050163772A1 (en) 2003-06-16 2005-07-28 University Of Washington B7S1: an immune modulator
WO2005052121A2 (en) 2003-11-21 2005-06-09 Archemix Corp. Multivalent aptamers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006053110A2 (en) 2004-11-10 2006-05-18 Diadexus, Inc. Ovr110 antibody compositions and methods of use
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1868647A4 (en) 2005-03-24 2009-04-01 Millennium Pharm Inc OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
WO2006121991A2 (en) 2005-05-06 2006-11-16 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of breast cancer
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8609816B2 (en) * 2005-12-08 2013-12-17 Medarex, L.L.C. Human monoclonal antibodies to O8E
US20090215084A1 (en) 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
MX2008009220A (es) 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US9121853B2 (en) 2006-03-20 2015-09-01 Mayo Foundation For Medical Education And Research B7-H4 expression on tumor vasculature
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2007124361A2 (en) 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2008051919A2 (en) 2006-10-23 2008-05-02 Acco Brands Usa Llc Security apparatus
AU2007325283B2 (en) * 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
EP2586458B1 (en) 2006-12-27 2016-08-24 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
AU2008261951A1 (en) 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US20110020325A1 (en) 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
US20120014947A1 (en) 2010-07-16 2012-01-19 The University Of Chicago Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012145568A1 (en) 2011-04-21 2012-10-26 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to human b7x for treatment of metastatic cancer
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
JP6359031B2 (ja) 2012-12-21 2018-07-18 メディミューン，エルエルシー 抗ｈ７ｃｒ抗体
MX2015010777A (es) 2013-03-14 2016-04-25 Genentech Inc Anticuerpos e inmunoconjugados anti-b7-h4.
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP2997373A1 (en) 2013-05-17 2016-03-23 MedImmune, LLC Receptors for b7-h4
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2015094782A1 (en) 2013-12-18 2015-06-25 Albert Einstein College Of Medicine Of Yeshiva University B7x and its derivatives for treating and preventing cardiovascular disease
EP3087099A4 (en) 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2015112534A2 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
CN107172880B (zh) 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
US10927410B2 (en) 2014-10-17 2021-02-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
US10626176B2 (en) 2014-10-31 2020-04-21 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind B7-H4
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
JP2018518151A (ja) 2015-03-27 2018-07-12 ユニバーシティ オブ サザン カリフォルニア Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞
SMT202100467T1 (it) 2015-04-17 2021-09-14 Alpine Immune Sciences Inc Proteine immunomodulatorie con affinità regolabili
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
EP3325512B1 (en) 2015-07-23 2023-09-06 Inhibrx, Inc. Multivalent and multispecific gitr-binding fusion proteins
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
EP3350206A1 (en) 2015-09-14 2018-07-25 Alpine Immune Sciences, Inc. Tunable variant immunoglobulin superfamily domains and engineered cell therapy
WO2017058754A1 (en) 2015-09-28 2017-04-06 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
US20190048094A1 (en) 2016-02-24 2019-02-14 Oncomed Pharmaceuticals, Inc. Redirecting immune responses
HUE064857T2 (hu) 2016-03-04 2024-04-28 Io Biotech Aps Kombinációs terápia a rák ellen
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
HRP20220237T1 (hr) 2016-05-20 2022-04-29 Biohaven Therapeutics Ltd. Primjena riluzola, prolijekova riluzola ili analoga riluzola sa imunoterapijama za liječenje raka
CA3035262A1 (en) 2016-09-16 2018-03-22 Tina Christine Lavranos Antibody and checkpoint inhibitor combination therapy
US10042000B2 (en) 2016-10-13 2018-08-07 Stmicroelectronics (Grenoble 2) Sas Method and apparatus for high frequency analog-to-digital conversion
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
GB201618291D0 (en) 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
AU2017363309A1 (en) 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
IL307242B1 (en) 2016-12-07 2026-07-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
CN107299085B (zh) 2017-05-26 2020-09-29 广东医科大学 分泌抗人b7-h4胞外单克隆抗体杂交瘤细胞株和抗人b7-h4单克隆抗体及其应用
SG11202000387YA (en) * 2017-08-25 2020-03-30 Five Prime Therapeutics Inc B7-h4 antibodies and methods of use thereof
AU2019226009B2 (en) 2018-02-21 2025-11-20 Five Prime Therapeutics, Inc. B7-H4 antibody dosing regimens
WO2019165077A1 (en) * 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
AU2019361923B2 (en) 2018-10-15 2026-07-09 Five Prime Therapeutics, Inc. Combination therapy for cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100483A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2015017600A1 (en) 2013-08-01 2015-02-05 Five Prime Therapeutics, Inc. Afucosylated anti-fgfr2iiib antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Cancer Letters，2012年，Vol.317，pp.99-105
Cell Reports，2014年，Vol.9，pp.1089-1098
DENARDA DANGAJ; ET AL，BLOCKING THE B7-H4 PATHWAY WITH NOVEL RECOMBINANT ANTIBODIES ENHANCES T CELL-以下備考，ONCOIMMUNOLOGY，2013年08月，VOL:2, NR:8，PAGE(S):E25913-1 - E25913-3，http://dx.doi.org/10.4161/onci.25913，MEDIATED ANTITUMOR RESPONSES
Monoclonal Antibodies，2014年，Vol.33, No.4，pp.270-274
ONCOIMMUNOLOGY，2013年08月，Vol.2, No.8，pp:E25913-1 - E25913-3
ONCOIMMUNOLOGY，2013年08月，VOL:2, NR:8，PAGE(S):E25913-1 - E25913-3

Also Published As

Publication number Publication date
UA128472C2 (uk) 2024-07-24
PE20200797A1 (es) 2020-08-10
TW202423980A (zh) 2024-06-16
IL321706A (en) 2025-08-01
CN111094352B (zh) 2024-10-01
CR20250168A (es) 2025-06-20
JP2024042117A (ja) 2024-03-27
US20240043542A1 (en) 2024-02-08
US20230013293A1 (en) 2023-01-19
SG11202000387YA (en) 2020-03-30
KR102761792B1 (ko) 2025-02-04
CL2023002239A1 (es) 2024-03-08
AU2018321902A1 (en) 2020-02-13
MX2020002076A (es) 2020-03-24
CL2020000452A1 (es) 2020-08-21
TWI817952B (zh) 2023-10-11
AU2018321902B2 (en) 2025-06-05
WO2019040780A1 (en) 2019-02-28
US12679892B2 (en) 2026-07-14
US20190085080A1 (en) 2019-03-21
BR112020003533A2 (pt) 2020-11-17
EP3672990A1 (en) 2020-07-01
US20200255528A1 (en) 2020-08-13
MA49950A (fr) 2020-07-01
ECSP20020111A (es) 2020-04-22
CL2025002111A1 (es) 2025-10-24
PH12020500368A1 (en) 2021-01-25
AU2025220883A1 (en) 2025-09-18
KR20200038305A (ko) 2020-04-10
CO2020001955A2 (es) 2020-04-01
JP2021500853A (ja) 2021-01-14
JP7802101B2 (ja) 2026-01-19
CA3070774A1 (en) 2019-02-28
KR20240138135A (ko) 2024-09-20
MX2025009210A (es) 2025-09-02
IL272274A (en) 2020-03-31
TW201920279A (zh) 2019-06-01
JP2026053725A (ja) 2026-03-25
MX2025009209A (es) 2025-09-02
CN111094352A (zh) 2020-05-01
CN119552248A (zh) 2025-03-04
IL272274B1 (en) 2025-08-01
US11306144B2 (en) 2022-04-19
US11814431B2 (en) 2023-11-14
CL2025002241A1 (es) 2025-10-24
CR20200138A (es) 2020-06-14
TWI870011B (zh) 2025-01-11
IL272274B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
JP7802101B2 (ja) Ｂ７－ｈ４抗体及びその使用方法
EP3558365B1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
KR102522693B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
CA3056972A1 (en) Anti-ox40 antibody and use thereof
CN114729038A (zh) Cd39的高亲和力抗体及其用途
US20210332137A1 (en) Combination therapy for cancer
US20240317864A1 (en) B7-h4 antibody dosing regimens
CN116997357A (zh) 针对gdf-15的抗体
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
AU2019251289B2 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
EP4540289A2 (en) Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
EA046814B1 (ru) Антитела к b7-h4 и способы их применения
WO2025137093A1 (en) Uses for attenuated il-2 immunoconjugates
HK40027698A (en) B7-h4 antibodies and methods of use thereof
HK40027698B (en) B7-h4 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150